LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC),…
CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under…
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies…
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy --…
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18…
Poster presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant…
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment…
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18,…
LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it…